In the present study, we address this gap by examining a cohort of pregnant women from Northeast China, to elucidate the association between glypican-4 and the risk of developing GDM, as well as its potential effects on insulin therapy and postpartum glucose metabolism in GDM patients for the first time. Here, GPC4 is linked to gestational diabetes.